

**NOT FOR PUBLICATION**

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

<hr/>		)	
ALBANY MOLECULAR RESEARCH,	)		
INC. and SANOFI-AVENTIS U.S. LLC,	)		
	)		
Plaintiffs,	)		
	)		
v.	)	Civil Action No. 09-4638 (GEB-MCA)	
	)		
DR. REDDY’S LABORATORIES, LTD. and	)		<b>ORDER</b>
DR. REDDY’S LABORATORIES,	)		
INC.,	)		
	)		
	)		
Defendants.	)		
<hr/>		)	

**BROWN, Chief Judge**

This matter having come before the Court upon the application for emergency relief pursuant to FED. R. CIV. P. 65 and L. CIV. R. 65.1 by Plaintiffs Albany Molecular Research, Inc. and Sanofi-Aventis U.S., LLC. (collectively “plaintiffs” or “AMRI” and “Aventis,” respectively), seeking a preliminary injunction against Defendant Dr. Reddy’s Laboratories, LTD and Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s” or “DRL”), enjoining Dr. Reddy’s from launching commercial sales in the United States of its fexofenadine hydrochloride/pseudophedrine hydrochloride 180 mg/240 mg extended release tablet products under Abbreviated New Drug Application No. 79-043 that allegedly infringe United States Patent No. 7,390,906 (the “’906 patent”), and the Court having conducting a hearing on May 27-28, received additional briefing on the claim construction issue, and heard closing arguments on June 7, and for the reasons

stated in the Memorandum Opinion accompanying this Order,

IT IS THIS 14<sup>th</sup> day of June, 2010

**ORDERED** that the plaintiffs' application is GRANTED, and Dr. Reddy's is preliminarily enjoined from launching commercial sales in the United States of its fexofenadine hydrochloride/pseudophedrine hydrochloride 180mg/240mg extended release tablet products under Abbreviated New Drug Application No. 79-043 that infringe, or contribute to or induce infringement of United States Patent No. 7,390,906; and it is further

**ORDERED** that the bond shall be set at \$20 million US Dollars, \$10 million of which having already been deposited in connection with the Temporary Restraining Order; and it is further

**ORDERED** that in the event a generic 24 hour fexofenadine hydrochloride/pseudophedrine hydrochloride 180 mg/240 mg extended release tablet product authorized by any plaintiff is offered for sale or sold in the United States at any time while this preliminary injunction is in effect, then this preliminary injunction shall automatically expire without further order of this Court immediately upon such offer for sale or sale.

s/ Garrett E. Brown, Jr.  
GARRETT E. BROWN, JR., U.S.D.J.

